CVS Health (CVS)
NYSE: CVS · Healthcare Plans · Woonsocket, RI
Our rating: Cautious
Call changed from Neutral to Cautious at $81.33, moderate conviction, November 5, 2026.
Breaks if: The Cautious call is invalidated if reported net margin recovers above 1.5% in either of the next two annual filings, signaling that the healthcare-benefits squeeze is genuinely easing and that amortization — not operating weakness — was the dominant drag on 2026 earnings. A stock move above $98 within twelve months, unaccompanied by that fundamental improvement, would also force a reassessment of what the market is crediting that the reported figures have not yet shown.
Key figures
| Market value | $103.4B |
|---|---|
| Revenue, last 12 months | $420.6B |
| Net income, last 12 months | $11.0B |
| Free cash flow, last 12 months | $15.6B |
| Price to earnings | 9.4× |
| Free cash flow yield | 15.1% |
| Dividend yield | 3.3% |
| Operating margin | 3.6% |
| Return on equity | 14.4% |
| Beta to the S&P 500 | 0.23 |
| Volatility, annualized | 34.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $108.4B | 5.4% | $1.68 | $3.9B |
| June 30, 2026 | $106.1B | 7.3% | $2.31 | $5.7B |
| March 31, 2026 | $100.4B | 6.2% | $2.30 | $3.4B |
| December 31, 2025 | $105.7B | 8.2% | $2.32 | $2.6B |
| September 30, 2025 | $102.9B | 7.8% | $-3.13 | $98M |
| June 30, 2025 | $98.9B | 8.4% | $0.80 | $1.3B |
| March 31, 2025 | $94.6B | 7.0% | $1.41 | $3.8B |
| December 31, 2024 | $97.7B | 4.2% | $1.31 | $1.1B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $112.8B: Claude 62%, Gemini 70%, Mistral 45%
- Diluted earnings per share are at least $2.32: Claude 45%, Gemini 40%, Mistral 40%
- Free cash flow for the quarter is at least $2.61B: Claude 48%, Gemini 85%, Mistral 65%
14 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.